Understanding the structural and regulatory mechanisms differentiating late INa from peak INa is essential for developing safe and selective therapies for Nav1.5-associated cardiac arrhythmias.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Wilde et al. (2002) conducted a review in Nav1.5-associated diseases (e.g., LQT3, cardiac arrhythmias). Late sodium current (late INa) modulators was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: